Cassava Sciences: With Almost Half The Float Shorted, Results Could Be Interesting
Cassava Sciences' stock is highly shorted, with potential reward tied to the upcoming Phase 3 trial results for simufilam.
Cassava Sciences’ Q3 2024: Financials and Alzheimer’s Trials Progress
Cassava Sciences ( (SAVA) ) has released its Q3 earnings. Here is a breakdown of the information Cassava Sciences presented to its investors.
Benzinga.com8h
Friday's Top 5 Trending Stocks: What's The Scoop On GameStop, SoFi, Tesla?
The stock has been up 30% since Tuesday, and its market cap has now reached more than $1 trillion. SAVA: Cassava Sciences is ...
STAT12h
Another U.S. biotech based on Chinese science
More U.S. investors are launching companies stateside that license technology from China, even as Congress moves to crack down on some Chinese companies through the BIOSECURE Act. Read more.